Open Access

Resveratrol fails to provide prophylactic protection in a rat model of organophosphate poisoning

  • Yossi Rosman1, 2,
  • Shaul Ravfogel1,
  • Arthur Shiyovich1,
  • Shai Shrot1,
  • Nadav Milk1,
  • Nimrod Ophir1,
  • Michael Aviram3,
  • Ishai Nir1,
  • Michael Kassirer1 and
  • Arik Eisenkraft1, 4, 5Email author
Contributed equally
Disaster and Military MedicineThe Journal of Prehospital, Trauma and Emergency Care20162:11

DOI: 10.1186/s40696-016-0021-8

Received: 13 March 2016

Accepted: 30 June 2016

Published: 26 July 2016

Abstract

Background

Paraoxonase-1, an organophosphorous-hydrolyzing enzyme, was shown to provide protection against organophosphates poisoning in vivo. In vitro findings suggest that the phytoalexin resveratrol can elevate paraoxonase-1 levels and thus may provide protection against organophosphate poisoning. This study was conducted to evaluate the effect of prolonged resveratrol intake on paraoxonase-1 levels in rats, and its role as a potential prophylactic treatment in organophosphate poisoning.

Methods

30 adult male albino Sprague–Dawley rats were randomly assigned into three groups: rats receiving no resveratrol (Control group, n = 10), rats treated once daily with oral gavage of ethanol only (Sham group, n = 6), and rats treated once daily with oral gavage of resveratrol (50 mg/kg) (Study group, n = 14). Following 2 weeks of feeding, all rats were exposed to 1.4LD50 paraoxon (450 mg/kg, intramuscular; 0.5 ml/kg) and monitored for severity of clinical signs and mortality. Paraoxonase-1 activity level was recorded in the beginning of the study and 2 weeks later, just before exposure to paraoxon.

Results

We found a significant decrease in paraoxonase-1 activity levels in all groups compared to baseline levels (p = 0.05), but no significant difference was observed between the study group and the controls (p = 0.7). Following exposure to paraoxon, all animals suffered from severe convulsions and died within minutes.

Conclusions

Following resveratrol intake in rats, paraoxonase-1 activity levels decreased. We found no beneficial effects in using resveratrol as a prophylactic medical countermeasure.

Keywords

Organophosphates Nerve agents Pre-treatment Prophylaxis Bioscavengers Medical countermeasure Resveratrol PON-1

Background

Organophosphate (OP) nerve agents (NAs) pose an imminent threat to both warfighters and civilian population [1]. Due to the toxic nature of NAs, efforts are aimed at introducing advanced pre-treatment and prophylactic medical countermeasures to the field, which will enable enhanced survival with less morbidity of soldiers in case of exposure. Pyridostigmine bromide is an accepted pre-treatment measure [2]. However, it provides only minor protection against OP poisoning, and helps mainly through enhancement of the protection provided by the post exposure antidotal mixture [2]. It does not protect from OP-induced major CNS symptoms and is not considered to be a prophylactic measure [3]. These drawbacks have resulted in active search of substitute compounds.

An ideal prophylactic compound will enable sufficient levels of functional cholinesterase; is expected to be active against a wide range of OPs and NAs; provide protection by itself, even without any post-exposure treatment; can be taken in a simple way; have a high safety profile and without side-effects; and will provide a long-lasting effect [46].

There are several families of prophylactic compounds, defined based on their mode of action. Detoxifying prophylactic compounds include stoichiometric and catalytic bioscavengers. Stoichiometric scavengers bind permanently and neutralize the OPs. These include acetylcholine esterase (AChE) and butyrylcholine esterase (BChE), with effects against all OPs, including NAs [7]. Several transgenic and recombinant systems were developed so far [8, 9] but none have reached full maturity and marketing due to several draw-backs, mainly in upscale techniques, immunogenicity, shelf life, large quantities needed for effective treatment, and price. Catalytic scavengers include several hydrolytic enzymes [10]. Unlike the stoichiometric scavengers, a relatively low dose of the catalytic scavengers should suffice to hydrolyze large quantities of OPs [11]. Despite good results in terms of preventing clinical poisoning [12, 13], these compounds are less broad-spectrum in nature, though efforts are made to make them as such [14, 15]. One of the candidate catalytic scavengers is human paraoxonase-1 (PON-1), a high-density lipoprotein-associated calcium-dependent organophosphate-hydrolase [16], which is mainly induced and secreted by the liver [17]. It was shown already to have a potential protective effect against OP poisoning [18]. Moreover, lack of PON-1 in mice increased OP toxicity [19]. The induction of this endogenous enzyme biosynthesis, has led to increased activity of the human PON-1 gene promoter, followed by elevated activity of serum PON-1, providing protection against OP exposure in rats [18].

The phytoalexin resveratrol is a potent antioxidant that displays antiplatelet, anti-neoplastic, anti-inflammatory and neuroprotective properties [20, 21], and is commercially available as a food supplement. Gouedard et al. showed increased in vitro expression of the HuPON-1 gene following exposure to resveratrol [22]. Moreover, increased expression of human PON-1 resulted in in vitro protection against soman and sarin simulants [23]. To The best of our knowledge there are no published data regarding resveratrol’s ability to increase plasma levels of PON-1 in vivo.

The aim of the current preliminary study was to assess whether pre-treatment with resveratrol can provide protection against OP exposure in a rat model.

Methods

Animals

Following institutional review board approval, 30 adult male albino Sprague–Dawley rats (300–320 g, Harlan-biotech, Jerusalem, Israel) were housed under standard laboratory conditions in plastic cages, three per cage, in a controlled environment with a constant temperature of 21 ± 2 °C and 12 h light/dark cycles. Food (Teklad certified global 18 % protein) and water were available ad libitum. All experiments were designed and performed in accordance with the statutes from “The guide for the care and use of laboratory animals in research” of the Ben-Gurion University of the Negev. This study complies with the Animal Welfare Act and other federal regulations which were approved by the Animal Care Committee. All procedures were performed under the supervision of a veterinarian.

Drugs

Paraoxon was purchased from Sigma Chemical Co. (Israel) and diluted in a vehicle containing 40 % propylene glycol. Resveratrol was purchased in a commercially-available form of capsules, each containing 100 mg resveratrol dissolved in ethanol (Solgar, Israel).

Study design

Animals were randomly divided into three groups: (1) rats receiving no resveratrol (Control group, n = 10); (2) rats treated once daily with oral gavage of ethanol only (Sham group, n = 6); and (3) rats treated once daily with oral gavage of resveratrol (50 mg/kg) (Study group, n = 14). Following 2 weeks of feeding, during which animals’ weight was followed, all rats were exposed to 1.4LD50 paraoxon (450 mg/kg, intramuscular; 0.5 ml/kg) and monitored for severity of clinical signs and mortality. Clinical score was defined as follows: (0) no activity, quiet periods; (1) chewing and facial clonus; (2) tremors and focal convulsions; and (3) severe generalized tonic–clonic convulsions.

Laboratory tests

PON-1 activity level was measured in the beginning of the study and 2 weeks after the oral supplementation of resveratrol, just before exposure to paraoxon. PON-1 activity level was analyzed as described by Aviram and Rosenblat [24]. Briefly, 5 µl aliquots of serum were analyzed. The basal assay mixture included 1.0 mM phenyl acetate in “activity buffer”. Phenyl acetate hydrolysis was kinetically monitored for 3 min (every 15 s) at 270 nm. One unit of PON-1 arylesterase activity is equivalent to 1 µmol of phenyl acetate hydrolyzed/min/ml.

Statistical analysis

Statistical analyses were performed using SPSS V.19 software. Data are presented as mean and standard error (SE) for continuous variables. Comparisons between groups were done using Student’s t test for continuous variables and with the Chi square test for categorical variables. p < 0.05 was considered significant.

Results

Out of 10 animals in the control group, one died during the two-week period before the poisoning.

Baseline levels of PON-1 activity were similar among the treatment, control and sham groups (p = 0.3; Table 1; Fig. 1). After 2 weeks of feeding with resveratrol, no increase in PON-1 activity level was found. On the contrary, all groups demonstrated a small yet significant decrease in the enzyme activity levels as compared to baseline levels (p = 0.05; Table 1; Fig. 1). No significant difference between the groups was demonstrated after 2 weeks, in comparison to the corresponding baseline activity levels (p = 0.7).
Table 1

PON-1 activity levels, before exposure (baseline, 0) and 14 days after exposure to 1.4LD50 paraoxon

 

Time (days)

Average enzyme activity (U/ml)

P

Control group (n = 9)

0

689.8 ± 16.9

0.05

14

657.6 ± 35.3

Treatment group (n = 14)

0

670.5 ± 13.6

0.05

14

607.6 ± 28.3

Sham group (n = 6)

0

650.1 ± 20.8

0.05

14

615.6 ± 43.2

Fig. 1

PON-1 activity levels, baseline (before exposure) and 14 days after exposure; *P = 0.05

A statistically significant and rather steady increase in body weight was observed during the 2 weeks of feeding (p < 0.01). No significant difference was noted between the study group and both the sham and control groups (p = 0.07).

All animals developed severe convulsions (score 3) and died, within 1–3 min and 10 min, respectively, following paraoxon exposure. Cause of death was respiratory failure.

Discussion

Maintaining sufficient levels of functional cholinesterase is a major goal of a prophylactic or pre-treatment approach against NA poisoning [5]. Other requirements include also long-lasting effect, high availability, and lack of side effects. These goals could, theoretically, be achieved by various means: decreasing the levels of active OP molecules within the bloodstream, elevating the levels of cholinesterases in the bloodstream and in various tissues, elevating the concentration of endogenous and exogenous detoxifying enzymes, protecting cholinesterases from inhibition, and reactivation of inhibited enzyme [3, 5, 6].

In the current study, based on in vitro data, we have tested the efficacy of pre-treatment with resveratrol in a rat model of paraoxon poisoning. During the 14-day feeding phase preceding the exposure, we followed the animals’ weight. The change in weight implies that no serious health effects were caused by resveratrol. However, when looking at PON-1 activity levels in serum, we found no elevation in PON-1 activity levels in animals pre-treated with resveratrol. Also, all animals, including the study group, died shortly after exposure to paraoxon with no difference in survival time. Because of the rapid death, neither a comparison between the groups, nor an examination of clinical signs over an extended period of time after poisoning was possible.

There are several possible explanations for these results: (1) taking into consideration the lack of information regarding the therapeutic window of resveratrol in OP poisoning, the dose given was possibly too low to provide protection. We adjusted the dose of the compound based on the report of Williams et al. that administered resveratrol to rats at doses of 50–500 mg/kg/day during a 28-days period with no side effects [25]. The lack of a dose–response curve may lead to the theoretical possibility that the resveratrol dose was not sufficient in order to sufficiently-influence PON1 levels. However, the fact that PON1 levels did not increase and even significantly decreased during the treatment time suggest that resveratrol does not increase PON1 levels in the rat model; (2) the compound we used was of commercial origin, as a food additive, and as such contains several other compounds besides resveratrol. This may have influenced our results; (3) in this preliminary study pre-treatment was not accompanied by a standard antidotal treatment post exposure. One may argue that it should be tested in a protocol that includes post-exposure treatment. However, one of the goals in finding a new pre-treatment compound is to show it can exert its beneficial effects without post-exposure treatment. As such, resveratrol pre-treatment was found to be ineffective. In case of positive results, the next step would have been to define dose–response curves and study its role in an extended protocol including post-exposure treatment; (4) it has been reported that the bioavailability of oral resveratrol in humans is negligible, with only trace amounts of the original compound detected in the bloodstream [26]. Another study in rats showed similar results of s relatively low bioavailability [27]. Therefore, it is possible that the method of administration we used is not suitable for demonstrating the full therapeutic effect of the compound; (5) it is possible that resveratrol does not influence PON-1 levels in rats. Actually, to the best of our knowledge, this is the first time the relation between resveratrol and PON-1 is studied in vivo, in rats. (6) We did not find any data in the literature regarding PON1 levels in rats over time. We speculate that aging of the rats may have some effect on PON1 levels but this speculation is not based on hard data.

In relation to the exposure protocol, 1.4LD50 of paraoxon is a clinically significant dose, considered to be relevant for testing the efficacy and the potential role of medical countermeasures candidates, mainly in terms of counteracting severe signs of poisoning and enhancing survival, in a sort of go-no-go approach for future studies of a compound, especially in-light of the vast efforts needed to complete full development and fielding.

Another issue regards the possible role of resveratrol as post-exposure treatment. Since exposure to NAs results in a fast and severe clinical deterioration, post-exposure treatment requirements include immediate clinical effect as demonstrated, for example, by the anticholinergic drug atropine. Unfortunately, even if a compound like resveratrol has a positive effect on levels of PON1, it is notable only after a long period-of-time, thus not relevant for post-exposure treatment.

Conclusions

Since no protection was afforded to pre-treated animals, our current results do not support the use of resveratrol as a pre-treatment measure against OP poisoning. However, this was a preliminary study, using a commercial formulation and not the pure compound. Thus, in vivo research is still relevant in order to further evaluate the possible influence of food supplements on PON-1 activity levels and resveratrol-PON1 dose–response curve in particular. Once completed, these supplements may be tested in a more advanced protocol as a protective prophylactic measure against OP poisoning.

Notes

Abbreviations

OP: 

organophosphate

NA: 

nerve agent

PON-1: 

paraoxonase 1

AChE: 

acetylcholine esterase

BChE: 

butyrylcholine esterase

Declarations

Authors’ contributions

IN, AE and YR conceived the study. SS and AS participated in the design of the study. All authors participated in the study and data collection. AS performed the statistical analysis. YR, SR and AE drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Shira Ovadia from the Ben-Gurion University for her invaluable help. This study was supported by a Grant from the IDF Medical Corps, No. 634-2007.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Israel Defense Forces Medical Corps
(2)
The Sackler Faculty of Medicine, Tel Aviv University
(3)
Lipid Research Laboratory, Technion Faculty of Medicine, Rambam Medical Center
(4)
The Institute for Research in Military Medicine, The Faculty of Medicine, The Hebrew University of Jerusalem
(5)
NBC Protection Division, Israel Ministry of Defense

References

  1. Rosman Y, Eisenkraft A, Milk N, Shiyovich A, Ophir N, Shrot S, et al. Lessons learned from the Syrian sarin attack: evaluation of a clinical syndrome through social media. Ann Intern Med. 2014;160(9):644–8.View ArticlePubMedGoogle Scholar
  2. Sidell FR, Newmark J, McDonough JH. Chapter 5: Nerve agents. Medical aspects of chemical warfare. In: Tuorinsky SD, editor. Textbook of military medicine. Washington DC: Office of the Surgeon General, US Army, Borden Institute, Walter Reed Army Medical Center; 2008. p. 155–220.Google Scholar
  3. Layish I, Krivoy A, Rotman E, Finkelstein A, Tashma Z, Yehezkelli Y. Pharmacologic prophylaxis against nerve agent poisoning. IMAJ. 2005;7(3):182–7.PubMedGoogle Scholar
  4. Patocka J, Jun D, Bajgar J, Kuca K. Prophylaxis against nerve agent intoxications. Def Sci J. 2006;56(5):775–84.View ArticleGoogle Scholar
  5. Kassa J, Bajgar J, Kuca K, Musílek K, Karasová J. The present approaches to the development of prophylactic and therapeutic antidotes against nerve agents. Interdiscip Toxicol. 2008;1(1):18–21.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Bajgar J, Fusek J, Kassa J, Kuca K, Jun D. Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr Med Chem. 2009;16(23):2977–86.View ArticlePubMedGoogle Scholar
  7. Bird SB, Dawson A, Ollis D. Enzymes and bioscavengers for prophylaxis and treatment of organophosphate poisoning. Front Biosci (Scholar edition). 2009;2:209–20.Google Scholar
  8. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46(6):1239–47.View ArticlePubMedGoogle Scholar
  9. Huang YJ, Wang B, Lazaris A, Leduc M, Bilodeau AS, Bellemare A, et al. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. PNAS. 2007;104(34):13603–8.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Masson P, Josse D, Lockridge O, Viguié N, Taupin C, Buhler C. Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning. J Physiol-Paris. 1998;92(5):357–62.View ArticlePubMedGoogle Scholar
  11. Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, Cerasoli DM. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology. 2007;233(1):31–9.View ArticlePubMedGoogle Scholar
  12. Raveh L, Segall Y, Leader H, Rothschild N, Levanon D, Henis Y, et al. Protection against tabun toxicity in mice by prophylaxis with an enzyme hydrolyzing organophosphate esters. Biochem Pharmacol. 1992;44(2):397–400.View ArticlePubMedGoogle Scholar
  13. Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. PNAS. 2008;105(35):12780–4.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Goldsmith M, Ashani Y, Simo Y, Ben-David M, Leader H, Silman I, et al. Evolved stereoselective hydrolases for broad-spectrum G-type nerve agent detoxification. Chem Biol. 2012;19:456–66.View ArticlePubMedGoogle Scholar
  15. Cherny I, Greisen P Jr, Ashani Y, Khare SD, Oberdorfer G, Leader H, et al. Engineering V-type nerve agents detoxifying enzymes using computationally focused libraries. ACS Chem Biol. 2013;8(11):2394–403.View ArticlePubMedGoogle Scholar
  16. Josse D, Masson P. Human plasma paraoxonase (HuPON1): an anti-atherogenic enzyme with organophosphate hydrolase activity. Ann Pharm Fr. 2001;59(2):108–18 (French).PubMedGoogle Scholar
  17. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem. 2002;277(6):4301–8.View ArticlePubMedGoogle Scholar
  18. Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol. 1990;103(1):66–76.View ArticlePubMedGoogle Scholar
  19. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394(6690):284–7.View ArticlePubMedGoogle Scholar
  20. Virgili M, Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci Lett. 2000;281(2–3):123–6.View ArticlePubMedGoogle Scholar
  21. Sengottuvelan M, Senthilkumar R, Nalini N. Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim Biophys Acta. 2006;1760(8):1175–83.View ArticlePubMedGoogle Scholar
  22. Gouedard C, Barouki R, Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscl Throm Vasc Biol. 2004;24(12):2378–83.View ArticleGoogle Scholar
  23. Curtin BF, Seetharam KI, Dhoieam P, Gordon RK, Doctor BP, Nambiar MP. Resveratrol induces catalytic bioscavenger paraoxonase 1 expression and protects against chemical warfare nerve agent toxicity in human cell lines. J Cell Biochem. 2008;103(5):1524–35.View ArticlePubMedGoogle Scholar
  24. Aviram M, Rosenblat M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases (Clifton, NJ). Methods Mol Biol. 2008;477:259–76.View ArticlePubMedGoogle Scholar
  25. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 2009;47(9):2170–82.View ArticlePubMedGoogle Scholar
  26. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377–82.View ArticlePubMedGoogle Scholar
  27. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2011;68(3):593–601.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2016

Advertisement